Low-dose imatinib mesylate causing subdural hematoma in remission phase of chronic myeloid leukemia: A rare phenomenon

2018 ◽  
Vol 2 (2) ◽  
pp. 29
Author(s):  
RajeshKumar Singh ◽  
VijayKumar Mishra ◽  
Souvik Chaudhuri ◽  
Manjula Sinha
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Imatinib Mesylate ◽  
Subdural Hematoma ◽  
Myeloid Leukemia ◽  
Low Dose ◽  
Rare Phenomenon ◽  
Remission Phase

scholarly journals A case of subdural hematoma in patient with chronic myeloid leukemia treated with high-dose imatinib mesylate

2010 ◽  
Vol 45 (1) ◽  
pp. 73 ◽  
Author(s):  
Min Sik Kim ◽  
Dong Hyun Lee ◽  
Yu Rim Lee ◽  
Dong Kyun Kim ◽  
Suk Hyang Bae ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Imatinib Mesylate ◽  
Subdural Hematoma ◽  
Myeloid Leukemia ◽  
High Dose

Sustained molecular response in chronic myeloid leukemia deep responders treated with low dose tyrosine kinase inhibitors

2017 ◽  
Vol 59 (3) ◽  
pp. 766-769 ◽  
Author(s):  
Emilie Cayssials ◽  
Florence Tartarin ◽  
Joëlle Guilhot ◽  
Nathalie Sorel ◽  
Jean Claude Chomel ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Myeloid Leukemia ◽  
Low Dose ◽  
Kinase Inhibitors ◽  
Molecular Response

Effects of imatinib mesylate on normal bone marrow cells from chronic myeloid leukemia patients in complete cytogenetic response

2009 ◽  
Vol 33 (1) ◽  
pp. 170-173 ◽  
Author(s):  
Fermin M. Sanchez-Guijo ◽  
Jesus M. Hernandez ◽  
Eva Lumbreras ◽  
Patricia Morais ◽  
Carlos Santamaría ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Chronic Myeloid Leukemia ◽  
Imatinib Mesylate ◽  
Myeloid Leukemia ◽  
Bone Marrow Cells ◽  
Cytogenetic Response ◽  
Normal Bone Marrow ◽  
Normal Bone ◽  
Complete Cytogenetic Response ◽  
Marrow Cells
Sign in / Sign up

Export Citation Format

Share Document